{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:40:24Z","timestamp":1789926024314,"version":"4.0.1"},"reference-count":177,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.01024","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:01:50Z","timestamp":1594389710000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses"],"prefix":"10.3389","volume":"11","author":[{"given":"Alice","family":"Nevone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Nuvolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/nri3553","article-title":"The immunobiology of prion diseases","volume":"13","author":"Aguzzi","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/(SICI)1098-1004(1997)9:3<226::AID-HUMU3>3.0.CO;2-5","article-title":"Screening and biochemical characterization of transthyretin variants in the Portuguese population","volume":"9","author":"Alves","year":"1997","journal-title":"Hum. Mutat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0006-291X(02)00465-5","article-title":"Only amyloidogenic intermediates of transthyretin induce apoptosis","volume":"294","author":"Andersson","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B6","first-page":"1","article-title":"Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden","volume":"590","author":"Andersson","year":"1976","journal-title":"Acta Med. Scand. Suppl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00277-006-0187-0","article-title":"Localized Castleman\u2019s disease associated with systemic AA amyloidosis. Regression of amyloid deposits after tumor removal","volume":"86","author":"Androulaki","year":"2007","journal-title":"Ann. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archneur.1968.00470360015001","article-title":"Polyneuritic amyloidosis in a Japanese family","volume":"18","author":"Araki","year":"1968","journal-title":"Arch. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/s0387-7604(84)80061-3","article-title":"Type I familial amyloidotic polyneuropathy (Japanese type)","volume":"6","author":"Araki","year":"1984","journal-title":"Brain Dev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","article-title":"Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy","volume":"108","author":"Aus dem Siepen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"B13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/13506129.2013.854766","article-title":"Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan\/dexamethasone","volume":"21","author":"Bochtler","year":"2014","journal-title":"Amyloid"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/s0140-6736(01)05411-3","article-title":"Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues","volume":"358","author":"Bruce","year":"2001","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/ejhf.1563","article-title":"Real-world versus trial patients with transthyretin amyloid cardiomyopathy","volume":"21","author":"Canepa","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"B20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/acn3.568","article-title":"Two novel PRNP truncating mutations broaden the spectrum of prion amyloidosis","volume":"5","author":"Capellari","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur. Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"B25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"B26","first-page":"179","article-title":"A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET","volume-title":"J. Rheumatol.","author":"Coelho","year":"1993"},{"key":"B27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1021\/acs.jmedchem.9b01037","article-title":"Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes","volume":"62","author":"Corazza","year":"2019","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","article-title":"Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area","volume":"263","author":"Cortese","year":"2016","journal-title":"J. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006304","article-title":"Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease","volume":"2","author":"De Strooper","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"746","DOI":"10.7326\/0003-4819-134-9_part_1-200105010-00011","article-title":"Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease","volume":"134","author":"Dember","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acn3.748","article-title":"C1QA and C1QC modify age-at-onset in familial amyloid polyneuropathy patients","volume":"6","author":"Dias","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/13506129.2019.1584892","article-title":"One year follow up analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"26","author":"Edwards","year":"2019","journal-title":"Amyloid"},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study()","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-Human Phase I\/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/13506129.2019.1615428","article-title":"Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)","volume":"26","author":"Ghilardi","year":"2019","journal-title":"Amyloid"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur. Heart J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstrom","year":"2001","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","article-title":"Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons","volume":"19","author":"Hartley","year":"1999","journal-title":"J. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2249.1990.tb03339.x","article-title":"A primed state exists in vivo following histological regression of amyloidosis","volume":"81","author":"Hawkins","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/ndt\/gfv276","article-title":"Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010","volume":"31","author":"Hoshino","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"B53","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ajh.24453","article-title":"Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation","volume":"91","author":"Hwa","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/13506129.2019.1582508","article-title":"Patient profile with ATTR-FAP and evaluation of the safety and efficacy of tafamidis meglumine in Japan - interim analysis in post-marketing surveillance","volume":"26","author":"Ishii","year":"2019","journal-title":"Amyloid"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/ki.1997.262","article-title":"Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study","volume":"51","author":"Jadoul","year":"1997","journal-title":"Kidney Int."},{"key":"B56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/sdi.12720","article-title":"Hemodialysis-related amyloidosis: Is it still relevant","volume":"31","author":"Kaneko","year":"2018","journal-title":"Semin. Dial."},{"key":"B58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cardfail.2019.01.006","article-title":"Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis","volume":"25","author":"Karlstedt","year":"2019","journal-title":"J. Card. Fail"},{"key":"B59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3109\/13506129.2011.597464","article-title":"Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis","volume":"18","author":"Kluve-Beckerman","year":"2011","journal-title":"Amyloid"},{"key":"B61","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"Kollmer","year":"2015","journal-title":"Brain"},{"key":"B62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"20483","DOI":"10.1073\/pnas.1008255107","article-title":"Trapping of palindromic ligands within native transthyretin prevents amyloid formation","volume":"107","author":"Kolstoe","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/ajh.23827","article-title":"Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias","volume":"89","author":"Kourelis","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/qjmed\/95.4.211","article-title":"Unicentric Castleman\u2019s disease complicated by systemic AA amyloidosis: a curable disease","volume":"95","author":"Lachmann","year":"2002","journal-title":"QJM"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/art.37827","article-title":"AA amyloidosis complicating the hereditary periodic fever syndromes","volume":"65","author":"Lane","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B72","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"key":"B73","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13506129.2017.1352503","article-title":"Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"key":"B74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"key":"B76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer Disease: An Update on Pathobiology and Treatment Strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079104","article-title":"Depletion of spleen macrophages delays AA amyloid development: a study performed in the rapid mouse model of AA amyloidosis","volume":"8","author":"Lundmark","year":"2013","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.1090187","article-title":"Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis","volume":"302","author":"Mallucci","year":"2003","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuron.2007.01.005","article-title":"Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice","volume":"53","author":"Mallucci","year":"2007","journal-title":"Neuron"},{"key":"B80","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000049070","article-title":"Remission of nephrotic syndrome due to AA amyloidosis and initiation of glomerular repair after surgical resection of localized Castleman\u2019s disease","volume":"90","author":"Mandreoli","year":"2002","journal-title":"Nephron"},{"key":"B81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41408-018-0137-9","article-title":"Deferred autologous stem cell transplantation in systemic AL amyloidosis","volume":"8","author":"Manwani","year":"2018","journal-title":"Blood Cancer J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174152","article-title":"Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity","volume":"12","author":"Martin","year":"2017","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/13506129.2018.1456425","article-title":"A functional assay to identify amyloidogenic light chains","volume":"25","author":"Martin","year":"2018","journal-title":"Amyloid"},{"key":"B86","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ene.12905","article-title":"\u2018PrP systemic deposition disease\u2019: clinical and pathological characteristics of novel familial prion disease with 2-bp deletion in codon 178","volume":"23","author":"Matsuzono","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light Chain (AL) Amyloidosis: The Journey to Diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1056\/NEJMoa1214747","article-title":"A novel prion disease associated with diarrhea and autonomic neuropathy","volume":"369","author":"Mead","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1182\/asheducation-2012.1.595","article-title":"Differential diagnosis of monoclonal gammopathy of undetermined significance","volume":"2012","author":"Merlini","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4\u2019-iodo-4\u2019-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"92","author":"Merlini","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.bbmt.2018.09.019","article-title":"Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplantation","volume":"24","author":"Mikhael","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B96","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"B97","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J. Med. Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study","volume":"4","author":"Minamisawa","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/13506129.2013.803463","article-title":"Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis","volume":"20","author":"Montagna","year":"2013","journal-title":"Amyloid"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"515","DOI":"10.7326\/0003-4819-151-7-200910060-00017","article-title":"Localized amyloidosis at the site of enfuvirtide injection","volume":"151","author":"Morilla","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.carpath.2019.05.002","article-title":"The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis","volume":"42","author":"Morris","year":"2019","journal-title":"Cardiovasc. Pathol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"B107","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14728222.2017.1398235","article-title":"Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis","volume":"21","author":"Nuvolone","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"B109","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/ndt\/gfw305","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.febslet.2009.06.014","article-title":"Cells and prions: a license to replicate","volume":"583","author":"Nuvolone","year":"2009","journal-title":"FEBS Lett."},{"key":"B111","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/13506129.2012.711391","article-title":"AA-Amyloid is cleared by endogenous immunological mechanisms","volume":"19","author":"Nystrom","year":"2012","journal-title":"Amyloid"},{"key":"B112","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.autrev.2012.07.016","article-title":"Amyloidosis in autoinflammatory syndromes","volume":"12","author":"Obici","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"B113","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"B114","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/blood.V130.Suppl_1.1760.1760","article-title":"Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis","volume":"130","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/13506129.2017.1289917","article-title":"Prognostication of survival and progression to dialysis in AA amyloidosis","volume":"24","author":"Palladini","year":"2017","journal-title":"Amyloid"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"B120","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, Amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"B121","doi-asserted-by":"publisher","first-page":"9992","DOI":"10.1073\/pnas.1300761110","article-title":"AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin","volume":"110","author":"Penchala","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B122","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/ajh.2830460306","article-title":"Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman\u2019s disease","volume":"46","author":"Perfetti","year":"1994","journal-title":"Am. J. Hematol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12882-017-0698-z","article-title":"Doxycycline treatment in dialysis related amyloidosis: discrepancy between antalgic effect and inflammation, studied with FDG-positron emission tomography: a case report","volume":"18","author":"Piccoli","year":"2017","journal-title":"BMC Nephrol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1600-6143.2012.04326.x","article-title":"Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance","volume":"13","author":"Pinney","year":"2013","journal-title":"Am. J. Transplant."},{"key":"B125","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","article-title":"Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study","volume":"264","author":"Plante-Bordeneuve","year":"2017","journal-title":"J. Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clml.2019.07.003","article-title":"Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End","volume":"19","author":"Premkumar","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B127","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1002\/art.22959","article-title":"Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival","volume":"56","author":"Prokaeva","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","article-title":"Shattuck lecture\u2013neurodegenerative diseases and prions","volume":"344","author":"Prusiner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"B131","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and Survival Trends in Amyloidosis 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/anie.200351179","article-title":"Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action","volume":"42","author":"Razavi","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component","volume":"373","author":"Richards","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/humu.23669","article-title":"Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience","volume":"40","author":"Rowczenio","year":"2019","journal-title":"Hum. Mutat."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/13506129.2017.1375908","article-title":"Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier","volume":"24","author":"Rubin","year":"2017","journal-title":"Amyloid"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat. Commun."},{"key":"B141","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/ejhg.2015.180","article-title":"Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M)","volume":"24","author":"Santos","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"B142","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/jnnp-2017-316657","article-title":"mtDNA copy number associated with age of onset in familial amyloid polyneuropathy","volume":"89","author":"Santos","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B143","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.25409","article-title":"Large normal alleles of ATXN2 decrease age at onset in transthyretin familial amyloid polyneuropathy Val30Met patients","volume":"85","author":"Santos","year":"2019","journal-title":"Ann. Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399402004647","article-title":"Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies","volume":"4","author":"Saraiva","year":"2002","journal-title":"Expert Rev. Mol. Med."},{"key":"B145","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/IJNRD.S84784","article-title":"Dialysis-related amyloidosis: challenges and solutions","volume":"9","author":"Scarpioni","year":"2016","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"B146","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1182\/blood.V130.Suppl_1.4552.4552","article-title":"Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis Results in Improved Hematologic Response Rates: a Single Institution 11 Year Experience","volume":"130","author":"Scharman","year":"2017","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/hdi.12057","article-title":"Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients","volume":"18","author":"Schiffl","year":"2014","journal-title":"Hemodial. Int."},{"key":"B148","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jacc.2017.11.037","article-title":"Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement","volume":"71","author":"Scully","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","author":"Scully","year":"2020","journal-title":"Eur. Heart J."},{"key":"B150","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"B151","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains","volume":"32","author":"Sidana","year":"2018","journal-title":"Leukemia"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/ajh.25566","article-title":"Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis","volume":"94","author":"Sidana","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ajh.25746","article-title":"Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis","volume":"95","author":"Sidana","year":"2020","journal-title":"Am. J. Hematol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","article-title":"Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time","volume":"36","author":"Sidiqi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"16115","DOI":"10.1073\/pnas.1306621110","article-title":"Pathogenetic mechanisms of amyloid A amyloidosis","volume":"110","author":"Simons","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B157","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/s0002-9440(10)63050-7","article-title":"Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates","volume":"159","author":"Sousa","year":"2001","journal-title":"Am. J. Pathol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release","volume":"72","author":"Sperry","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ajpath.2012.12.035","article-title":"Efficient amyloid A clearance in the absence of immunoglobulins and complement factors","volume":"182","author":"Sponarova","year":"2013","journal-title":"Am. J. Pathol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","article-title":"Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis","volume":"4","author":"Staron","year":"2020","journal-title":"Blood Adv."},{"key":"B162","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/13506120009146835","article-title":"Four structural risk factors identify most fibril-forming kappa light chains","volume":"7","author":"Stevens","year":"2000","journal-title":"Amyloid"},{"key":"B163","first-page":"108","article-title":"Iatrogenic, insulin-dependent, local amyloidosis","volume":"48","author":"Storkel","year":"1983","journal-title":"Lab. Invest."},{"key":"B164","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann. Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","article-title":"Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study","volume":"24","author":"Ueda","year":"2011","journal-title":"Mod. Pathol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1073\/pnas.1901947116","article-title":"Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development","volume":"116","author":"Vallabh","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B167","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1179\/acb.2005.006","article-title":"Localised plasma-cell type Castleman\u2019s disease and AA-amyloidosis cured by resection. A case report and review of the literature","volume":"60","author":"Verbrugghe","year":"2005","journal-title":"Acta Clin. Belg."},{"key":"B168","first-page":"479","article-title":"On the formation and disappearance of amyloid in man","volume":"63","author":"Waldenstrom","year":"1928","journal-title":"Acta Chir. Scand."},{"key":"B169","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J."},{"key":"B171","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/13892037113149990050","article-title":"Islet amyloid polypeptide and diabetes","volume":"14","author":"Westermark","year":"2013","journal-title":"Curr. Protein Pept. Sci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA amyloidosis: pathogenesis and targeted therapy","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/s0140-6736(96)91412-9","article-title":"A new variant of Creutzfeldt-Jakob disease in the UK","volume":"347","author":"Will","year":"1996","journal-title":"Lancet"},{"key":"B175","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12265-019-09895-0","article-title":"Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome","volume":"12","author":"Zegri-Reiriz","year":"2019","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.1200\/JCO.2019.37.15_suppl.8010","article-title":"Seeking light-chain amyloidosis very early: The SAVE trial\u2014identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma","volume":"37","author":"Zhou","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1056\/NEJM199010113231514","article-title":"Beta 2-microglobulin amyloidosis in chronic renal failure","volume":"323","author":"Zingraff","year":"1990","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01024\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:01:55Z","timestamp":1594389715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01024\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":177,"alternative-id":["10.3389\/fphar.2020.01024"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.01024","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"article-number":"1024"}}